Genscript Biotech Corporation
GNNSF · OTC
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Market Cap | $2,595,034 | $2,694,033 | $3,386,564 | $5,120,566 |
| - Cash | $293,206 | $131,990 | $399,297 | $1,479,074 |
| + Debt | $548,519 | $170,568 | $448,128 | $417,739 |
| Enterprise Value | $2,850,347 | $2,732,611 | $3,435,395 | $4,059,231 |
| Revenue | $518,773 | $33,115 | $561,371 | $448,711 |
| % Growth | 1,466.6% | -94.1% | 25.1% | – |
| Gross Profit | $320,631 | -$34,861 | $306,986 | $234,763 |
| % Margin | 61.8% | -105.3% | 54.7% | 52.3% |
| EBITDA | $208,929 | $187,973 | -$117,937 | -$51,699 |
| % Margin | 40.3% | 567.6% | -21% | -11.5% |
| Net Income | -$25,462 | $3,136,992 | -$175,115 | -$1,898 |
| % Margin | -4.9% | 9,473% | -31.2% | -0.4% |
| EPS Diluted | -0.012 | 1.44 | -0.083 | -0.001 |
| % Growth | -100.8% | 1,841.2% | -9,088.9% | – |
| Operating Cash Flow | $232,619 | -$4,208 | $79,855 | -$95,927 |
| Capital Expenditures | -$32,126 | -$13,894 | -$134,026 | -$76,499 |
| Free Cash Flow | $200,493 | -$18,102 | -$54,171 | -$172,426 |